What is PET-CT Scanning?

A PET-CT scan combines two imaging techniques: Positron Emission Tomography (PET) and Computed Tomography (CT). The PET scan uses a small amount of radioactive tracer to show how tissues and organs are functioning, while the CT scan uses X-rays to produce

images of the different density or thickness of organs in your body. Together, they give a very detailed and accurate internal picture which a referring specialist can use to help diagnose and if necessary, decide the most effective treatment.

We're the NHS England Contract Holder

Over the past decade, Alliance Medical has been a pivotal player in supporting the NHS to expand its PET-CT network. We deliver NHS PET-CT services to 80% of England, lead the Molecular Imaging Collaborative Network and manufacture and distribute PET radiopharmaceuticals at 5 UK sites.

Investing in digital PET-CT

As a leader in molecular imaging, we have improved accessibility and cancer pathways by investing in PET-CT and introducing new digital PET-CT scanners across the UK. This innovative technology has superior image quality and exposes patients to lower radiation.

It also allows cancer to be detected at the very earliest stages, vastly improving treatment options and outcomes. This has been crucial in providing life-saving diagnostic imaging to hundreds of thousands of patients across England and reducing the cost burden on the healthcare system.

Specialist centres

We currently have five specialist centres in the UK at sites in Guildford, Sidcup, Leeds, Norwich and London. By the end of 2025, we will launch three more digital PET-CT services at Oldham CDC, Sheffield and Portsmouth.

Types of tracers

FBB (Amyloid)
‍Also known as Florbetaben or 18F-florbetaben, FBB is primarily used to detect beta-amyloid plaques in the brain, which are a hallmark of Alzheimer's disease. The presence and distribution of these plaques can help in the diagnosis and assessment of Alzheimer's and other neurodegenerative conditions.

‍FDG
The FDG tracer is one of the most used radiopharmaceuticals in PET-CT imaging and is primarily used to assess metabolic activity in tissues. It is widely employed in oncology for cancer detection, staging, and monitoring treatment response. Additionally, it is used in cardiology and neurology for evaluating heart conditions and brain disorders.
‍
F-18 PSMA
18F-PSMA tracer is available at all of our PET-CT centres, helping to meet demand for detection of prostate cancer. A highly sensitive tracer, 18F-PSMA can detect very small prostate cancer lesions, allowing for earlier detection and more accurate staging, which is crucial for treatment planning.

Navigation

About Our Story Leadership News and Press Contact us

What we do CDCs Mobiles Radiopharmacy PET-CT

Get in touch

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Cookies Policy

Terms and Conditions

Modern Slavery Act

Company Registration Number: 02128897